You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

82 Results
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
ODB - General Benefit
    dexamethasone
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
carfilzomib (Unfunded),
dexamethasone,
selinexor (Unfunded)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Mar 2024
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Lymphocytic (CLL)
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    zanubrutinib - For the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) who have received at least one prior therapy; and for the treatment of adult patients with previously untreated CLL.
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
zanubrutinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Mar 2024
Drug
Other Name(s): Xpovio®
Quick Link(s): Drug Monograph, Patient Info Sheet
Mar 2024
Guidelines and Advice
Status: Current
ID: GL 19-7
Mar 2024
Guidelines and Advice
Status: Current
ID: C50-CIDAP-1
Mar 2024
Drug
Other Name(s): Sarclisa®
Quick Link(s): Drug Monograph, Patient Info Sheet
Mar 2024
Guidelines and Advice
Status: Archived
ID: 20-3
Jan 2016
Guidelines and Advice
Status: Current
ID: 17-4
Version: 2
Nov 2016
Statistical Reports
Jun 2016
Guidelines and Advice
Status: In-Review
ID: 3-14
Version: 2
Sep 2016

Pages